BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 26710763)

  • 1. Clinical Performance of APTIMA Human Papillomavirus (HPV) 16 18/45 mRNA Genotyping Testing for the Detection of Cervical Intraepithelial Neoplasia 3 (CIN3) or Cancer in a Select Group of Chinese Women.
    Guo YL; You K; Geng L; Qiao J
    Pathol Oncol Res; 2016 Jul; 22(3):549-54. PubMed ID: 26710763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
    Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
    Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Linear array genotyping and hybrid capture II assay in detecting human papillomavirus genotypes in women referred for colposcopy due to abnormal Papanicolaou smear.
    Monsonego J; Pollini G; Evrard MJ; Sednaoui P; Monfort L; Quinzat D; Dachez R; Syrjänen K
    Int J STD AIDS; 2008 Jun; 19(6):385-92. PubMed ID: 18595876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evaluation of CIN2+ /CIN3+ risk of different HPV subtypes infection combined with abnormal cytology status].
    Luo HX; Du H; Liu ZH; Zhang LJ; Wang C; Wu RF
    Zhonghua Zhong Liu Za Zhi; 2018 Mar; 40(3):232-238. PubMed ID: 29575846
    [No Abstract]   [Full Text] [Related]  

  • 5. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice.
    Khan MJ; Castle PE; Lorincz AT; Wacholder S; Sherman M; Scott DR; Rush BB; Glass AG; Schiffman M
    J Natl Cancer Inst; 2005 Jul; 97(14):1072-9. PubMed ID: 16030305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human papillomavirus (HPV) genotypes in women with cervical precancer and cancer at Kaiser Permanente Northern California.
    Castle PE; Shaber R; LaMere BJ; Kinney W; Fetterma B; Poitras N; Lorey T; Schiffman M; Dunne A; Ostolaza JM; McKinney S; Burk RD
    Cancer Epidemiol Biomarkers Prev; 2011 May; 20(5):946-53. PubMed ID: 21415357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of mRNA- and DNA-based high-risk human papillomavirus assays in detection of high-grade cervical lesions.
    Virtanen E; Kalliala I; Dyba T; Nieminen P; Auvinen E
    Acta Obstet Gynecol Scand; 2017 Jan; 96(1):61-68. PubMed ID: 27858961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triaging HPV-positive, cytology-negative cervical cancer screening results with extended HPV genotyping and p16
    Song F; Yan P; Huang X; Wang C; Qu X; Du H; Wu R
    BMC Infect Dis; 2021 Apr; 21(1):400. PubMed ID: 33931022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of measurements of human papillomavirus persistence for postcolposcopic surveillance for cervical precancerous lesions.
    Gage JC; Schiffman M; Solomon D; Wheeler CM; Castle PE
    Cancer Epidemiol Biomarkers Prev; 2010 Jul; 19(7):1668-74. PubMed ID: 20615884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term risk of cervical intraepithelial neoplasia grade 3 or worse according to high-risk human papillomavirus genotype and semi-quantitative viral load among 33,288 women with normal cervical cytology.
    Thomsen LT; Frederiksen K; Munk C; Junge J; Iftner T; Kjaer SK
    Int J Cancer; 2015 Jul; 137(1):193-203. PubMed ID: 25471319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical relevance of partial HPV16/18 genotyping in stratifying HPV-positive women attending routine cervical cancer screening: a population-based cohort study.
    Gori S; Battagello J; Gustinucci D; Campari C; Zorzi M; Frayle H; Passamonti B; Sartori G; Bulletti S; Fodero C; Cesarini E; Faggiano R; Del Mistro A
    BJOG; 2021 Jul; 128(8):1353-1362. PubMed ID: 33326680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The performance of human papillomavirus DNA detection with type 16/18 genotyping by hybrid capture in primary test of cervical cancer screening: a cross-sectional study in 10,669 Chinese women.
    Zhao X; Wu Q; Wang X; Fu Y; Zhang X; Tian X; Cheng B; Lu B; Yu X; Lan S; Lu W; Ma D; Cheng X; Xie X
    Clin Microbiol Infect; 2018 Dec; 24(12):1322-1327. PubMed ID: 29518562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities.
    Castle PE; Solomon D; Schiffman M; Wheeler CM
    J Natl Cancer Inst; 2005 Jul; 97(14):1066-71. PubMed ID: 16030304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence.
    Kjær SK; Frederiksen K; Munk C; Iftner T
    J Natl Cancer Inst; 2010 Oct; 102(19):1478-88. PubMed ID: 20841605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary cervical cancer screening and triage using an mRNA human papillomavirus assay and visual inspection.
    Nieves L; Enerson CL; Belinson S; Brainard J; Chiesa-Vottero A; Nagore N; Booth C; Pérez AG; Chávez-Avilés MN; Belinson J
    Int J Gynecol Cancer; 2013 Mar; 23(3):513-8. PubMed ID: 23334437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A study of genotyping for management of human papillomavirus-positive, cytology-negative cervical screening results.
    Schiffman M; Burk RD; Boyle S; Raine-Bennett T; Katki HA; Gage JC; Wentzensen N; Kornegay JR; Aldrich C; Tam T; Erlich H; Apple R; Befano B; Castle PE
    J Clin Microbiol; 2015 Jan; 53(1):52-9. PubMed ID: 25339396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HPV-mRNA and HPV-DNA detection in samples taken up to seven years before severe dysplasia of cervix uteri.
    Forslund O; Miriam Elfström K; Lamin H; Dillner J
    Int J Cancer; 2019 Mar; 144(5):1073-1081. PubMed ID: 30125346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of three human papillomavirus DNA assays and one mRNA assay in women with abnormal cytology.
    Rebolj M; Lynge E; Ejegod D; Preisler S; Rygaard C; Bonde J
    Gynecol Oncol; 2014 Dec; 135(3):474-80. PubMed ID: 25449563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk stratification of HPV-positive results using extended genotyping and cytology: Data from the baseline phase of the Onclarity trial.
    Stoler MH; Parvu V; Yanson K; Andrews J; Vaughan L
    Gynecol Oncol; 2023 Jul; 174():68-75. PubMed ID: 37149907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triaging HPV-positive women with normal cytology by p16/Ki-67 dual-stained cytology testing: baseline and longitudinal data.
    Uijterwaal MH; Polman NJ; Witte BI; van Kemenade FJ; Rijkaart D; Berkhof J; Balfoort-van der Meij GA; Ridder R; Snijders PJ; Meijer CJ
    Int J Cancer; 2015 May; 136(10):2361-8. PubMed ID: 25345358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.